TP 271

Drug Profile

TP 271

Alternative Names: TP-271

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Antibacterials; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Community-acquired pneumonia

Most Recent Events

  • 05 Jun 2017 Phase-I clinical trials in Community-acquired pneumonia (In volunteers) in USA (PO) (NCT03024034)
  • 05 Jun 2017 Adverse events data from a phase I trial in Community-acquired pneumonia released by Tetraphase Pharmaceuticals
  • 13 Jan 2017 Tetraphase Pharmaceuticals plans a phase I trial for community-acquired bacterial pneumonia in USA (NCT03024034)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top